Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
-
Field
-
for focal epilepsy with ultrasound neurorecording, modulation, and deep reinforcement learning (DRL) closed-loop control. The technology will be developed through detailed computer simulations and preclinical
-
-of-the-art in machine learning, (probabilistic) modelling, system identification and numerical optimization. How to apply Send your CV, containing one or more references, a copy of your diploma (if already in
-
. Digital Extraction from Historical Taxonomic Literature Application of OCR and machine learning algorithms to digitize printed and handwritten documents; Linking specimen mentions in literature to digital
-
frequently asked questions or send an email to jobs@uantwerpen.be . Questions about the scientific content of the position can be asked to Prof. Joke Hadermann, joke.hadermann@uantwerpen.be . The University
-
the selection procedure. If you have any questions about the online application form, please check the frequently asked questions or send an email to jobs@uantwerpen.be . For more information, you are welcome
-
procedure. If you have any questions about the online application form, please check the frequently asked questions or send an email to jobs@uantwerpen.be . For more information, you are welcome to contact
-
procedure. If you have any questions about the online application form, please check the frequently asked questions or send an email to jobs@uantwerpen.be . If you have any questions about the job itself
-
. IDLab staff counts about 50 professors, 60 Post Doc researchers, 200 PhD researchers and 40 other staff members. These are spread over about 20 research teams. The research for this PhD position will be
-
nanoelectronics and digital technologies. IDLab staff counts about 50 professors, 60 Post Doc researchers, 200 PhD researchers and 40 other staff members. These are spread over about 20 research teams. The research
-
) and T cells therapies (CAR-T) for cancer patients. These pharmaceutical products are cell and gene therapy products or advanced therapy medicinal products (ATMP). We recently finalized a phase I